Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10296015 | 0.97 | MMP1 (0.38) | MMP1MMP7MMP12ECE1MMP13 | |
| SCHEMBL12415514 | 0.97 | MMP1 (0.38) | MMP1MMP7MMP12ECE1MMP13 | |
| SCHEMBL17229702 | 0.94 | ADH1B (0.33) | MMP1MMP7MMP12ECE1MMP13 | |
| SCHEMBL2600354 | 0.88 | — | — | |
| SCHEMBL8481304 | 0.77 | GABRA1 (0.50) | — | |
| SCHEMBL2103979 | 0.77 | — | — | |
| SCHEMBL14667090 | 0.77 | PIK3CD (0.33) | — | |
| SCHEMBL15837580 | 0.75 | HTR2A (0.36) | — | |
| SCHEMBL4814249 | 0.75 | MMP1 (0.35) | MMP1MMP7MMP12ECE1MMP13 | |
| SCHEMBL20715145 | 0.74 | SMN1; SMN2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20200317678-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10723733-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10398677-B2 | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-09-03 | — | — | US | disclosed |
| US-20180162841-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20180153857-A1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-07 | — | — | US | disclosed |
| US-20140171427-A1 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-19 | — | — | US | disclosed |
| US-8372833-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-10-18 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095231-A1 | UREA DERIVATIVE | YANO TOSHISADA (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8088777-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | UCB SA (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20090203712-A1 | Urea Derivative | SHIONOGI &CO., LTD. | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | NNT, NAPRT, NNMT | MMP1 3436/4885MMP7 1884/4885MMP12 2287/4885 |
| US-10398677-B2 | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | HCCS, PYGL, XDH | MMP1 3797/4885MMP7 1554/4885MMP12 3527/4885 |
| US-20180153857-A1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | HCCS, PYGL, XDH | MMP1 3797/4885MMP7 1554/4885MMP12 3527/4885 |
| US-20140171427-A1 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, TRPV1, KCNJ1 | MMP1 4752/4885MMP7 4827/4885MMP12 4777/4885 |
| US-20180162841-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | MMP1 4233/4885MMP7 3552/4885MMP12 3765/4885 |
| US-20200317678-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | MMP1 2970/4885MMP7 583/4885MMP12 1524/4885 |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | MMP1 2771/4885MMP7 2378/4885MMP12 2778/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | MMP1 4752/4885MMP7 4827/4885MMP12 4777/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | MMP1 4644/4885MMP7 4553/4885MMP12 4309/4885 |
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | CDK2, CDK5, CDK5R1 | MMP1 1778/4885MMP7 986/4885MMP12 1234/4885 |
| US-20120095231-A1 | UREA DERIVATIVE | NPY5R, NPY1R, NPY2R | MMP1 4338/4885MMP7 881/4885MMP12 4222/4885 |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPM5, KCNQ1 | MMP1 4278/4885MMP7 4076/4885MMP12 4365/4885 |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | MMP1 4489/4885MMP7 2838/4885MMP12 4325/4885 |
| US-10723733-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | MMP1 2970/4885MMP7 583/4885MMP12 1524/4885 |
| US-20090203712-A1 | Urea Derivative | NPY5R, NPY1R, NPY2R | MMP1 4359/4885MMP7 945/4885MMP12 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.